Jinliang Chen

Friendship Road 1, Yuan Jiagang
Chongqing, 400016, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

CHRNA1 induces sarcopenia through neuromuscular synaptic elimination.

CHRNA1 induces sarcopenia through neuromuscular synaptic elimination.

Journal: Experimental gerontology

Published: April 26, 2022

The ameliorating effects of metformin on disarrangement ongoing in gastrocnemius muscle of sarcopenic and obese sarcopenic mice.

The ameliorating effects of metformin on disarrangement ongoing in gastrocnemius muscle of sarcopenic and obese sarcopenic mice.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: April 17, 2022

Lysyl oxidase-like 2 inhibitor rescues D-galactose-induced skeletal muscle fibrosis.

Lysyl oxidase-like 2 inhibitor rescues D-galactose-induced skeletal muscle fibrosis.

Journal: Aging cell

Published: November 01, 2021

Correction to: Ghrelin ameliorates nerve growth factor Dysmetabolism and inflammation in STZ-induced diabetic rats.

Correction to: Ghrelin ameliorates nerve growth factor Dysmetabolism and inflammation in STZ-induced diabetic rats.

Journal: Metabolic brain disease

Published: October 06, 2020

Expressions of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases 1 in skeletal muscles of aged rats with sarcopenia

Expressions of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases 1 in skeletal muscles of aged rats with sarcopenia

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: May 08, 2020

Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 diabetic db/db mice.

Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 diabetic db/db mice.

Journal: Life sciences

Published: January 11, 2020

Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.

Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.

Journal: Biochemical and biophysical research communications

Published: December 19, 2019

High glucose-induced complement component 3 up-regulation via RAGE-p38MAPK-NF-κB signalling in astrocytes: In vivo and in vitro studies.

High glucose-induced complement component 3 up-regulation via RAGE-p38MAPK-NF-κB signalling in astrocytes: In vivo and in vitro studies.

Journal: Journal of cellular and molecular medicine

Published: May 03, 2018

Protective Effects of Sulforaphane on Cognitive Impairments and AD-like Lesions in Diabetic Mice are Associated with the Upregulation of Nrf2 Transcription Activity.

Protective Effects of Sulforaphane on Cognitive Impairments and AD-like Lesions in Diabetic Mice are Associated with the Upregulation of Nrf2 Transcription Activity.

Journal: Neuroscience

Published: February 24, 2018

High glucose-induced defective thrombospondin-1 release from astrocytes via TLR9 activation contributes to the synaptic protein loss.

High glucose-induced defective thrombospondin-1 release from astrocytes via TLR9 activation contributes to the synaptic protein loss.

Journal: Experimental cell research

Published: October 27, 2017

Integrated study on comparative transcriptome and skeletal muscle function in aged rats.

Integrated study on comparative transcriptome and skeletal muscle function in aged rats.

Journal: Mechanisms of ageing and development

Published: October 20, 2017

High-glucose induces tau hyperphosphorylation through activation of TLR9-P38MAPK pathway.

High-glucose induces tau hyperphosphorylation through activation of TLR9-P38MAPK pathway.

Journal: Experimental cell research

Published: April 13, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026